


Leonhardt's Launchpads Inc

Operated by Cal-X Stars Business Accelerator, Inc.

Leonhardt's Launchpads, LIFE REGENERATED

World's First Organ Regeneration
Focused 5 Year Innovation Accelerator



Accelerating Breakthrough Regenerative
Medtech & Economy Startups for 5 Years

Howard J Leonhardt hleonhardt@aol.com



A Leonhardt
Ventures Co

The Problem



1) Large companies fail to innovate fast at low cost.



2) No other accelerator has organ regeneration core competence.



3) It costs too much for a startup to develop one biotech implantable product as a stand alone.



4) Existing drugs, devices and stand alone cell therapies do no regenerate organs.

Solution



Focus on what acquirers want to acquire. Patents + Data + Endorsements + Positive Press + Market Momentum.



Unmatched core competency in organ regeneration. Superior organ regeneration technologies.



80+ business veteran team members and scientists.



Bio-Leonhardt


www.calxstars.com




HOWARD LEONHARDT
CEO, LEONHARDT VENTURES

Market Size

The market for
regenerating all
major organs
of the body exceeds
\$500 billion



Business Model



.....

We accelerate startups for 5 years and then auction them off.

63X

ROI Target
After 5 Years

.....

We are designed to move valuations from \$2.3 million from year 1 to \$300 million at the end of year 5 while minimizing dilution.

\$6,300,000

Target 5 year return on
\$100,000 investment

.....

We have done it before.

Proprietary Technology / Expertise

✓ Over a dozen patents and patents pending for bioelectric signals for controlling protein expression.

✓ Patent on stem cell homing signal.




✓ Patent on controlling differentiation of stem cells to useful tissues.

✓ 15 component proprietary angiogenic and regeneration compositions.


✓ Three micro infusion pump patents.

Competition



The One Shot Stem Cell Cos.

Capricor, Cytori, Mesoblast, Cardio 3 NeoSTem, Osiris – stem cells delivered alone just once are nowhere even close enough to regenerate a major organ.



The Pacing Cos.

Medtronic, Boston Scientific, Guidant, BioTronik, Sorin Biomedica, Abbott St. Jude – wrong signals that do not recruit stem cells or build new tissue



The Drug Cos.

Pfizer, Gilead, Amgen, Samumed – Drugs do not regenerate organs

Leonhardt's Launchpads, Inc has unmatched capabilities in organ regeneration



A growing library of controlled bioelectric protein expression signals
- SDF-1, IGF-1, HGF, EGF, eNOS, VEGF, Follistatin, Tropelastin, Activin A+B, RANKL.

FluidSync™ M200 micro pump



Programmable, re-fillable, micro infusion pump.



15 component proprietary angiogenic and regeneration compositions.

Go-to Market Plan

Customer Acquisition Channels



1. A first focus on patents
2. Focus on getting data from a minimum of 20 patients
3. Opinion leader endorsements via education



1. Building support at trade shows.
2. Positive press and buzz.
3. Auction off at 5 year birthday discipline.

Founding Team



Howard Leonhardt
(CEO)

- Inventor of over 100 issued patent claims.
- Developed leading cardio caths in the 80's
- First Non-Surgical Stem Cell Repair of Heart 2001
- Leading stent graft and percutaneous heart valves in the 90's



Dr. Leslie Miller
(CMO)

- Heart failure Physician
- Helped lead numerous circulatory assist pump developments
- Editor Stem Cells Cardiovascular text book



Jeremy Koff
(VP Business Development)

- Helped lead a number of Alfred Mann Co. startups, including Advanced Bionics
- Alfred Mann's nephew
- Dir. Marketing Bioness NeuroStimulator

Our Startups




Leonhardt's Launchpads Inc.

Operated by Cal-X Stars Business Accelerator, Inc.



Money, Milestones



\$150k is budgeted for each startup
for pre-clinical, patents and
product development.
\$750k for OUS pilot trial.
That's it.



\$300 mil.

Target sell price after
year 5 and data on
minimum of 20 patients
confirming product
works

Raising - \$15,000,000

- HEART and CARDIOVASCULAR
= \$6,900,000
- BRAIN
= \$1,000,000
- COSMETIC and PERSONAL CARE
= \$1,950,000
- MAJOR ORGAN REGENERATION
= \$2,400,000
- CANCER
= \$1,000,000+
- REGENERATIVE ECONOMY
= \$850,000 including
accelerator/incubator overhead